CME GROUP INC.

CME GROUP INC. (CME) — Investment Memo

🐂 The Bull Case (Warren's voice)

• Moat durability: Network effects + switching costs create a self-reinforcing flywheel. Every new trader deepens liquidity → lower spreads → more traders. Firms have embedded CME’s products into risk systems, collateral workflows, and algos – moving would take years and billions. This toll booth on global derivatives won’t rust.

• Exceptional economics: 62.5% net margins (2025) – pricing power and near‑zero marginal cost. $4.2B free cash flow equals reported net income – no accounting games. Revenue compounded 6.1% annually from $3.6B (2016) to $6.5B (2025) – boring, steady, real. ROE doubled from 7.5% to 14.2% without leverage.

• Attractive entry: At a market price of ~$230 (current), the stock trades at 66% of intrinsic value (DCF = $346.45). That’s a 34% discount – above the 25% margin of safety threshold. Buffett would be comfortable buying a cash machine with a widening moat at that price. If it dips to $259 (25% safety), it’s a no‑brainer; at $173 (50% safety), he’d buy the whole company.

🐻 The Bear Case (Charlie inverts)

Munger’s rule: “Show me where I’ll die and I won’t go there.”

1. Crypto‑native exchange steals liquidity – A decentralized blockchain platform with near‑zero fees and instant settlement could draw volume away from CME’s centralized model. If that gains critical mass in 5–10 years, the toll booth empties. Likelihood? Low but rising. Timeframe: 10–15 years.

2. Regulatory gut‑punch – A shift to mandatory bilateral swaps (e.g., EU clearing mandate reversal) or a tax on derivatives trading would slash volume. CME’s revenue is pure volume‑sensitive. Unlikely in the short term, but a political black swan is permanent.

3. Goodwill hangover drags returns – ROA is 2.1% because a mountain of acquisition goodwill sits on the balance sheet. If management overpays for another deal (e.g., buying a struggling exchange for $10B+ ), the compounding slows to a crawl. Most likely threat over 5 years – watch acquisition discipline.

Most likely permanent impairment: #3 – management’s capital allocation (not the core business) is the weak link. They’ve earned trust so far, but one bad deal could destroy 10–15% of intrinsic value.

💰 Valuation & Margin of Safety

• Intrinsic value estimate: $346.45 per share (DCF: 11.5% FCF growth, 10% discount rate, 3% terminal growth). Assumes moat holds 20+ years – realistic given network effects.

• 25% margin of safety entry: $259.84 (buy at 75% of intrinsic – conservative)

• 50% margin of safety entry: $173.23 (Buffett’s ideal – rare entry)

• Current price (~$230): At a 34% discount to intrinsic – below the 25% safety threshold. Not a steal, but genuinely attractive. If you believe the DCF, this is a “fair‑to‑cheap” buy.

Verdict: BUY at current levels.

The moat is real, the economics are pristine, and the price offers a comfortable margin of safety against all but the most catastrophic tail risks. Management’s capital allocation is the only cloud – but their track record (zero debt, FCF = NI) earns a pass until they stumble.